Given the use of PPAR agonists in the management of clinical hypertriglyceridemia and in clinical trials for MASLD-associated steatohepatitis and fibrosis (6), understanding the molecular regulation of PPARɑ transcriptional activity may provide opportunities for control of metabolic dysfunction. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.